RSV

Ziresovir (RO-0529) is a respiratory syncytial virus fusion protein (RSV F) inhibitor that inhibits RSV activity and can be used in the study of syncytial virus sensing.

Totrombopag (SB559448) is a candidate compound for action on RSV polymerase.

Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.

VV116 is a selective and orally active nucleoside antiviral agent against respiratory syncytial virus and SARS-CoV-2 infection.[1]

Ac-CoA Synthase Inhibitor1 (ACSS2 inhibitor) is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2).

Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).

Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.

Roflumilast (APTA 2217) is an orally available, long-acting inhibitor of phosphodiesterase (PDE) type 4 (PDE4), with anti-inflammatory and potential antineoplastic activities. Upon administration, roflumilast and its active metabolite roflumilast N-oxide selectively and competitively bind to and inhibit PDE4, which leads to an increase of both intracellular levels of cyclic-3', 5'-adenosine monophosphate (cAMP) and cAMP-mediated signaling.

Amentoflavone (3',8''-Biapigenin), as a potent inhibitor of CYP3A4 and CYP2C9, can interact with many other medications. CYP3A4 and CYP2C9 are proteins used for drug metabolism in the body. Amentoflavone also is an inhibitor of human cathepsin B. It has antimalarial activity in trials significant affinities towards the Delta-1, kappa opioid receptors (as an antagonist) and binds to benzodiazepine receptors. Amentoflavone may be a potential lead for a new type of anti-inflammatory agents having the dual inhibitory activity of group II phospholipase A2 and cyclooxygenase. Amentoflavone and quercetin differentially exerted suppression of PGE2 biosynthesis via downregulation of COX-2/iNOS expression.

Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with a modified Fc region, efficiently targeting RSV-B with a Kd value of 1.5 nM, and can be used to prevent RSV infection.

BTA-9881 is a novel RSV fusion inhibitor with oral activity and antiviral activity for the study of respiratory syncytial virus infections.

RSV604 ((S)-1-(2-Fluorophenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)urea) is an inhibitor of respiratory syncytial virus (RSV) that binds to RSV nucleoprotein (Kd = 1.31 μM)

ALS-8112 (ALS 008112) is a selective and potent inhibitor of respiratory syncytial virus (RSV) polymerase with an IC50 value of 0.02 μM. ALS-8112 exhibits antiviral activity and inhibits the RNA polymerase activity of the RSV L-P protein complex through RNA chain termination. virus infections.

Presatovir (GS-5806) (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor (mean EC50: 0.43 nM).

Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.

TMC353121 is a respiratory syncytial virus (RSV) fusion inhibitor with anti-RSV activity that inhibits the production of the inflammatory cytokines TNF-α, IL-6, and IL-1β, as well as chemokines, KC, IP-10, MCP, and MIP1-α.

Sisunatovir hydrochloride (RV521 HCl) is an orally available inhibitor of the RSV-F protein that has exhibited potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses in vitro (IC50 = 1.4 nM for RSV-A, IC50 = 1.0 nM for RSV-B).

TNM001 is an anti-RSV fully humanized monoclonal antibody for the study of lower respiratory tract disease due to RSV infection.

RSM01 is a fully human IgG1 monoclonal antibody that targets a site in the pre-F region of RSV with a YTE half-life prolongation mutation.

Rostafuroxin (PST 2238) has been used in trials studying the treatment of Essential Hypertension.

KIN101 (3-(4-Bromophenyl)-7-[(methylsulfonyl)oxy]-4-oxo-4H-chromene), an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has antiviral activity against RNA viruses, HCV, and RSV.

Quercetin pentaacetate (Pentaacetylquercetin) has diverse biological activities, including antioxidant, anti-inflammatory, and anticancer properties. Quercetin pentaacetate interacts with RSV and inhibit the viral adhesion on cell surface.

RSV-IN-1 is an inhibitor of human respiratory syncytical virus (hRSV) and reduced the virus infectivity with IC50 value of 0.11 μM.

Suptavumab (REGN2222) is a human monoclonal antibody that neutralizes conserved epitopes on subtypes A and B of RSV, making it useful for studying RSV infections and the respiratory system.

AVG-233 is an orally available RNA-dependent RNA polymerase (RdRp) inhibitor with antiviral activity that blocks respiratory syncytial virus and SARS-CoV-2 replication.AVG-233 is used in the study of respiratory syncytial virus infections.

RSV L-protein-IN-4 (Compound C) is a noncompetitive inhibitor of the RSV polymerase, exhibiting an IC50 of 0.88 μM and demonstrating potent antiviral activity against RSV strains with an EC50 of 0.25 μM [1].

GS-441524 was shown to be a safe and effective treatment for feline infectious peritonitis (FIP). The optimum dosage was found to be 4.0 mg kg SC q24h for at least 12 weeks

RSV L-protein-IN-3 is an inhibitor of wild-type RSV polymerase with an IC50 of 10.4 μM and an EC50 of 2.1 μM (against RSV) and exhibits lower cytotoxicity than the clinical agent Ribavirin [1].

JNJ-8003 is a potent inhibitor of RSV Polymerase, impeding early RNA transcription and replication by inhibiting nucleotide polymerization [1].

RSV L-protein-IN-2 (Compound A) is a noncompetitive inhibitor of the RSV polymerase with an IC50 of 4.5 μM and demonstrates antiviral activity against long RSV strains with an EC50 of 1.3 μM [1].

Lumicitabine (ALS-008176) is an RSV polymerase inhibitor.

RSV L-protein-IN-5 (Compound E) serves as a potent inhibitor of the Respiratory Syncytial Virus (RSV), with an EC50 value of 0.1 μM. It targets RSV polymerase with an IC50 of 0.66 μM and impedes RSV mRNA synthesis through the inhibition of transcript guanylation. The compound demonstrates moderate cytotoxicity, with a CC50 of 10.7 μM in HEp-2 cells, and effectively reduces viral titers in mouse models of RSV infection [1].